Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CT-2103/Carboplatin for Patients With Newly Diagnosed Stage III or IV Ovarian or Primary Peritoneal Cancer: A Phase 2 Study

NCT00069901 is registered in ClinicalTrials.gov with CTI BioPharma as lead sponsor.

NCT NCT00069901
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00069901 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CT-2103/Carboplatin for Patients With Newly Diagnosed Stage III or IV Ovarian or Primary Peritoneal Cancer: A Phase 2 Study
Lead sponsor
CTI BioPharma
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2003
Completion date
September 30, 2006
Enrollment
82 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian neoplasm